Myocyte deficiency as a target in the treatment of cardiomyopathy

Claudia D Rodrigues, Lina Shehadeh, Keith A Webster, Nanette Bishopric

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cardiomyopathy is a general term referring to any disorder of cardiac muscle function, and can result from a number of defined and unknown acquired and congenital disorders; the end result is generally reduced contractile function and heart failure. Heart failure may occur early or late in the course of cardiomyopathy depending on the etiology and the age of the patient. How cardiomyopathic disorders lead to heart failure is incompletely resolved, particularly for disorders associated with hypertrophy. A leading hypothesis is that heart failure is effectively a myocyte deficiency disorder, reflecting the view that cardiomyopathy leads to cell loss and thence to heart failure. Several approaches for addressing this deficiency have been studied, including gene therapy targeting specific molecular events, cell therapy using myocytes from various sources, and a combination of gene and cell therapy using gene-modified cell transplantation. The recent discovery of populations of self-renewing progenitor cells residing in the myocardium raises the possibility of enhancing endogenous repair and regeneration mechanisms, and suggests additional levels at which genetic disorders may lead to impairment of myocardial function. Here we will review the evidence for myocyte dropout as a functionally significant phenomenon in human myocardial disorders, briefly discuss mechanisms and effectors of myocyte death, and their potential as targets in the treatment of cardiomyopathy. Finally, we will consider ways in which cell replacement therapy may eventually provide a solution to myocyte deficiency disorders.

Original languageEnglish
Pages (from-to)49-59
Number of pages11
JournalProgress in Pediatric Cardiology
Volume23
Issue number1-2
DOIs
StatePublished - Sep 1 2007

Fingerprint

Cardiomyopathies
Muscle Cells
Heart Failure
Cell- and Tissue-Based Therapy
Genetic Therapy
Myocardium
Therapeutics
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Inborn Genetic Diseases
Gene Targeting
Cell Transplantation
Hypertrophy
Regeneration
Stem Cells
Population
Genes

Keywords

  • Apoptosis
  • Cardiomyopathy
  • Cell death
  • Drug therapy
  • Genetics
  • Stem cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Myocyte deficiency as a target in the treatment of cardiomyopathy. / Rodrigues, Claudia D; Shehadeh, Lina; Webster, Keith A; Bishopric, Nanette.

In: Progress in Pediatric Cardiology, Vol. 23, No. 1-2, 01.09.2007, p. 49-59.

Research output: Contribution to journalArticle

@article{e5a4cac91a624881a4f07ced2cd0290f,
title = "Myocyte deficiency as a target in the treatment of cardiomyopathy",
abstract = "Cardiomyopathy is a general term referring to any disorder of cardiac muscle function, and can result from a number of defined and unknown acquired and congenital disorders; the end result is generally reduced contractile function and heart failure. Heart failure may occur early or late in the course of cardiomyopathy depending on the etiology and the age of the patient. How cardiomyopathic disorders lead to heart failure is incompletely resolved, particularly for disorders associated with hypertrophy. A leading hypothesis is that heart failure is effectively a myocyte deficiency disorder, reflecting the view that cardiomyopathy leads to cell loss and thence to heart failure. Several approaches for addressing this deficiency have been studied, including gene therapy targeting specific molecular events, cell therapy using myocytes from various sources, and a combination of gene and cell therapy using gene-modified cell transplantation. The recent discovery of populations of self-renewing progenitor cells residing in the myocardium raises the possibility of enhancing endogenous repair and regeneration mechanisms, and suggests additional levels at which genetic disorders may lead to impairment of myocardial function. Here we will review the evidence for myocyte dropout as a functionally significant phenomenon in human myocardial disorders, briefly discuss mechanisms and effectors of myocyte death, and their potential as targets in the treatment of cardiomyopathy. Finally, we will consider ways in which cell replacement therapy may eventually provide a solution to myocyte deficiency disorders.",
keywords = "Apoptosis, Cardiomyopathy, Cell death, Drug therapy, Genetics, Stem cells",
author = "Rodrigues, {Claudia D} and Lina Shehadeh and Webster, {Keith A} and Nanette Bishopric",
year = "2007",
month = "9",
day = "1",
doi = "10.1016/j.ppedcard.2007.05.001",
language = "English",
volume = "23",
pages = "49--59",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Myocyte deficiency as a target in the treatment of cardiomyopathy

AU - Rodrigues, Claudia D

AU - Shehadeh, Lina

AU - Webster, Keith A

AU - Bishopric, Nanette

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Cardiomyopathy is a general term referring to any disorder of cardiac muscle function, and can result from a number of defined and unknown acquired and congenital disorders; the end result is generally reduced contractile function and heart failure. Heart failure may occur early or late in the course of cardiomyopathy depending on the etiology and the age of the patient. How cardiomyopathic disorders lead to heart failure is incompletely resolved, particularly for disorders associated with hypertrophy. A leading hypothesis is that heart failure is effectively a myocyte deficiency disorder, reflecting the view that cardiomyopathy leads to cell loss and thence to heart failure. Several approaches for addressing this deficiency have been studied, including gene therapy targeting specific molecular events, cell therapy using myocytes from various sources, and a combination of gene and cell therapy using gene-modified cell transplantation. The recent discovery of populations of self-renewing progenitor cells residing in the myocardium raises the possibility of enhancing endogenous repair and regeneration mechanisms, and suggests additional levels at which genetic disorders may lead to impairment of myocardial function. Here we will review the evidence for myocyte dropout as a functionally significant phenomenon in human myocardial disorders, briefly discuss mechanisms and effectors of myocyte death, and their potential as targets in the treatment of cardiomyopathy. Finally, we will consider ways in which cell replacement therapy may eventually provide a solution to myocyte deficiency disorders.

AB - Cardiomyopathy is a general term referring to any disorder of cardiac muscle function, and can result from a number of defined and unknown acquired and congenital disorders; the end result is generally reduced contractile function and heart failure. Heart failure may occur early or late in the course of cardiomyopathy depending on the etiology and the age of the patient. How cardiomyopathic disorders lead to heart failure is incompletely resolved, particularly for disorders associated with hypertrophy. A leading hypothesis is that heart failure is effectively a myocyte deficiency disorder, reflecting the view that cardiomyopathy leads to cell loss and thence to heart failure. Several approaches for addressing this deficiency have been studied, including gene therapy targeting specific molecular events, cell therapy using myocytes from various sources, and a combination of gene and cell therapy using gene-modified cell transplantation. The recent discovery of populations of self-renewing progenitor cells residing in the myocardium raises the possibility of enhancing endogenous repair and regeneration mechanisms, and suggests additional levels at which genetic disorders may lead to impairment of myocardial function. Here we will review the evidence for myocyte dropout as a functionally significant phenomenon in human myocardial disorders, briefly discuss mechanisms and effectors of myocyte death, and their potential as targets in the treatment of cardiomyopathy. Finally, we will consider ways in which cell replacement therapy may eventually provide a solution to myocyte deficiency disorders.

KW - Apoptosis

KW - Cardiomyopathy

KW - Cell death

KW - Drug therapy

KW - Genetics

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=34547479770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547479770&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2007.05.001

DO - 10.1016/j.ppedcard.2007.05.001

M3 - Article

AN - SCOPUS:34547479770

VL - 23

SP - 49

EP - 59

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -